AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03022292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optovue angiovue
Description: FDA approved Optovue Angiovue will be used to monitor progression and responsiveness of active exudative macular degeneration to IAI.
Study NCT02895958 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zepatier
Description: Zepatier (elbasvir and grazoprevir +/- Ribavirin) will be administered in a community setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution therapy with Cirrhotic and Non-cirrhotic liver disease
Study NCT03979638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Four escalating doses of BLU-5937 administered BID over the course of the study
Study NCT03979638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for BLU-5937
Study NCT02661360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swaddling Intervention for Preterm Infants
Description: Procedure for swaddling includes folding one corner of the blanket down two thirds of the way down the blanket in order to make the blanket into a triangular shape. The infant will be positioned with shoulders at the fold of the blanket. The infant will be positioned with the blanket so that elbows, hips, and knees flexed with hands near the face by wrapping one side of the blanket across the chest holding the hands in place, pulling the bottom corner up toward the infant's face, and securing the blanket with the last corner pulled across the infant's chest again and around their back. The blanket will be tight enough to keep extremities in place but one finger will be able to be placed between the infant and the blanket.
Study NCT02661360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unswaddled Control
Description: Procedure for control is blanket loosely draped across the infant without providing containment and without touching the anterior surface of the infant.
Study NCT05810090 — intervention group
Intervention type: PROCEDURE
Intervention: Total knee arthroplasty
Description: patient who received a TKA in our hospital
Study NCT00628602 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BION
Description: 30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group).
Study NCT00628602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BION
Description: 30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group).
Study NCT03873870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga -DOTATATE PET scans
Description: PET scan using 68Ga-DOTATATE contrast
Study NCT03996798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disability Case Manager
Description: The DCM will act as key figure between the patient, the multidisciplinary team of the revalidation centre, the employers and other back-to-work services in order to increase vocational reintegration after an incident which caused a handicap or chronic disease.
Study NCT02003885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: increment of desflurane
Description: After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.~After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.~Reduction of BP is managed by the increment of phenylephrine infusion
Study NCT01674868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: 20 mg daily for 90 days starting day 5-10 after stroke.
Study NCT01674868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subjects will take one pill po daily for 90 days.
Study NCT02120573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Lecture and human model
Description: workshop to teach CPR with lecture and human models
Study NCT02120573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Educational Film
Description: workshops using film review about CPR
Study NCT02120573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Lecture, human model as well as Educational Film
Description: using educational films and human model and lecture for training
Study NCT02120573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop using Lecture, human model, Educational Film as well as reference book
Description: training volunteers with lecture, films, and human models and giving them reference book for referral
Study NCT01044095 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist® live, attenuated, intranasal seasonal influenza vaccine
Description: FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
Study NCT01044095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist® live, attenuated, intranasal seasonal influenza vaccine
Description: FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
Study NCT01044095 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® inactivated influenza virus vaccine
Description: Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
Study NCT01044095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® inactivated influenza virus vaccine
Description: Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
Study NCT00209079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gleevec, Taxotere
Description: Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
Study NCT04617691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as IV solution derived from FVP or PFS-U.
Study NCT00625027 — intervention group
Intervention type: OTHER
Intervention: Survey and Chart Review
Description: After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
Study NCT02735772 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transobturator approach for paravaginal repair
Description: using TOT needle to apply suturs to white line
Study NCT03851302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Remote Ischemic Conditioning
Description: The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.
Study NCT03851302 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning
Description: The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.
Study NCT03851302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric hand exercise
Description: Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
Study NCT03851302 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isometric hand exercise
Description: Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
Study NCT02800096 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gambling Internet intervention
Description: The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
Study NCT02800096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Internet intervention
Description: The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
Study NCT02800096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoodGYM
Description: Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
Study NCT01157819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% Ciprofloxacin Ear Drops
Description: 4 gtt b.i.d. for 7 days.
Study NCT01157819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FoamOtic Cipro
Description: 0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
Study NCT01224171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: Vedolizumab for intravenous infusion
Study NCT01224171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion
Study NCT03809702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
Study NCT03809702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
Study NCT02264444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cholecystectomy visualization
Description: Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
Study NCT03503188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Littmann ®
Description: electronic stethoscope
Study NCT02502994 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GEN0101
Study NCT03448458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT (Computed Tomography)
Description: Undergo PET/CT
Study NCT03448458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-DOTATATE
Description: Given IV
Study NCT03448458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04429269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mammography and ultrasound screening
Description: Patients screened by both mammography and ultrasound.
Study NCT01000311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
Study NCT01000311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib
Description: IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
Study NCT01000311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV
Description: IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
Study NCT01000311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV
Description: IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
Study NCT01000311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
Study NCT03079323 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PART-trial
Description: Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy
Study NCT04070131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Horse-Assisted Rehabilitation
Description: One hour weelky session of hippotherapy.
Study NCT02844751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [StroMed + platelet rich plasma (PRP)]
Description: \[Day 0\] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
Study NCT04420351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urokinase thrombolysis
Description: The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
Study NCT04420351 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin;Clopidogrel
Description: The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018.
Study NCT00818519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/Drospirenone (YAZ, BAY86-5300)
Description: 20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
Study NCT00818519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert tablet
Study NCT02181179 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The yoga intervention will be an 8-week program involving two 60-minute sessions each week at a local studio with three locations in Austin. Participants will be instructed to take classes deemed within a moderate-to-vigorous intensity dose. Participants will also be encouraged both by the PI and yoga instructors to complete the entire 60 minutes of yoga, urged to do only what is comfortable and not push themselves beyond their physical limits.
Study NCT02844751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [PRP] platelet rich plasma
Description: Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30
Study NCT02844751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [PRP] platelet rich plasma
Description: Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
Study NCT02780869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEMOBLAST Bellows
Study NCT02780869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable gelatin sponge, USP with thrombin
Study NCT00367380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 413ABM
Description: +/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
Study NCT00367380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 414WRR
Description: +/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
Study NCT00367380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 418JAL
Description: +/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
Study NCT01790659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279,396
Description: WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%
Study NCT01790659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin
Description: Paromomycin alone
Study NCT03639545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25mg
Description: The patients receive empagliflozin (25 mg daily) for 12 weeks.
Study NCT03639545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The patients receive metformin (2000 mg daily) for 12 weeks.
Study NCT03639545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin/Metformin
Description: The patients receive empagliflozin 25 mg daily and metformin 2000 mg daily or placebo for 12 weeks.
Study NCT01877629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-129968 500 mg tablet
Description: ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
Study NCT01877629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-129968 250 mg capsule
Description: ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
Study NCT03639545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The patients receive for 12 weeks.
Study NCT04235894 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Intravenous anesthesia with propofol started with 0.5 mg kg-1, and was titrated until a patient was unresponsive to painful stimuli \& maintaining spontaneous breathing during gastrointestinal endoscopy
Study NCT00440037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 531
Description: AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
Study NCT02482324 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ALZT-OP1a
Description: Mast cell stabilizer
Study NCT02482324 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ALZT-OP1b
Description: anti-inflammatory
Study NCT02482324 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dry Powder Inhaler
Description: The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
Study NCT02954809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning bright light therapy
Description: Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
Study NCT02954809 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dim light
Description: Exposure to dim light with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
Study NCT02985086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefoxitin
Study NCT02985086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin/misoprostol
Study NCT03091842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo supervised CARE program
Study NCT03091842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo supervised TARE program
Study NCT03091842 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Undergo home-based stretching program
Study NCT03091842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive instructional DVD and booklet of the flexibility exercises
Study NCT03091842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03091842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03091842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies